Indaptus Therapeutics Business Summary

Indaptus Therapeutics, Inc. (INDP) is a clinical-stage biotechnology company that operates through a drug discovery and development model focused on its proprietary Decoy platform. The company utilizes attenuated and killed non-pathogenic Gram-negative bacteria to activate both innate and adaptive immune pathways, targeting a broad range of oncology and infectious disease indications. Currently pre-revenue, Indaptus generates value through the clinical advancement of its lead candidate, Decoy20, with a long-term monetization strategy centered on potential licensing agreements, milestone-based partnerships, or strategic acquisitions. Within the competitive landscape of immunotherapy, the company contends with established players such as Jazz Pharmaceuticals, Kite Pharma (Gilead), and Xencor, Inc. Indaptus occupies a distinct niche as a developer of systemically administered, multi-target bacterial platforms designed to elicit broad-spectrum anti-tumor and anti-viral responses compared to more narrow antibody or cell-based therapies. Leadership is currently structured under a Co-CEO model featuring David E. Lazar, who serves as Chairman and Co-CEO following a strategic $6 million investment in late 2025, and Jeffrey A. Meckler, a veteran executive with over 30 years of experience at Pfizer and Cocrystal Pharma. The company was co-founded by Dr. Michael J. Newman, who serves as Chief Scientific Officer and brings a pedigree from Decoy Biosystems and academic oncology research, alongside Chief Operating Officer Walt A. Linscott, an experienced life sciences transactional strategist. The executive team is further bolstered by Chief Medical Officer Dr. Roger J. Waltzman, a former Novartis Oncology lead known for his work on Gleevec. Notable governance and investment support come from David E. Lazar and a board that includes industry veterans like Dr. Roger Pomerantz and recently appointed independent director David Natan, ensuring deep expertise in clinical development and capital markets.